ELAN vs ZTS vs ICCC Stock Comparison

Elanco Animal Health, Zoetis and Immucell Prices as of Nov 13, 2026 Peers: Industry group
ZTS Zoetis Inc.
$83.82 +11.3% 1M -30.8% 1Y
Market cap
$34.65B
P/E
13.8x
Revenue (TTM)
$9.49B
Div. yield
0.03%
Animal Health Healthcare
6 wins
ICCC Immucell Corp /De/
$10.75 0.0% 1M +77.7% 1Y
Market cap
$102.43M
P/E
54.5x
Revenue (TTM)
$33.21M
Div. yield
–
Animal Health Healthcare
5 wins

Head to Head

11 decided of 12

Zoetis leads on 6 of the 12 questions below (Zoetis 6, Immucell 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionELANZTSICCCLeader
Larger companyMarket capitalisation $13.25B $34.65B $102.43M ZTS
Cheaper on earningsLower P/E, profitable companies only -90.2x 13.8x 54.5x ZTS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 23.7x 14.1x — ZTS
Faster revenue growthRevenue growth, trailing twelve months +12.1% +0.9% +19.6% ICCC
More profitableNet margin, trailing twelve months -2.9% 26.4% 5.7% ZTS
Better return on capitalReturn on invested capital 6.9% 23.0% 11.7% ZTS
Less leveragedLower net debt / EBITDA 2.3x 1.9x 0.0x ICCC
Higher dividend yieldTrailing dividend yield 0.00% 0.03% 0.00% –
Better 1-year returnPrice return, last 12 months +21.8% -30.8% +77.7% ICCC
Better 5-year returnAnnualised price return, 5 years -4.1%/yr -17.3%/yr +3.1%/yr ICCC
Less volatileAnnualised volatility, 1 year 43.4% 39.7% 50.5% ZTS
Higher overall scoreMean of the five percentile scores vs peers 69/100 69/100 80/100 ICCC

Percentile Scorecard

ELANZTSICCC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisELANZTSICCC
Valuation 92 #52 of 660 85 #100 of 660 91 #63 of 660
Growth 67 #208 of 619 45 #342 of 619 88 #75 of 619
Profitability 85 #90 of 595 97 #22 of 595 90 #62 of 595
Financial Health 31 #473 of 683 31 #470 of 683 57 #298 of 683
Shareholder Returns 73 #126 of 459 88 #55 of 459 75 #115 of 459
Overall 69 69 80
  • ELAN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ZTS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ICCC ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodELANZTSICCCSPY
1 month +18.8%+11.3%0.0% -2.0%
3 months +13.2%+13.6%+7.0% -2.8%
6 months +34.9%+12.9%+20.5% +2.0%
Year to date +18.4%-33.4%+74.8% +10.6%
1 year +21.8%-30.8%+77.7% +12.2%
3 years +136.2%-51.5%+102.8% +68.1%
3 years, per year +33.2%-21.4%+26.6% +18.9%
5 years -18.9%-61.3%+16.6% +61.4%
5 years, per year -4.1%-17.3%+3.1% +10.1%
10 years —+65.6%+108.3% +248.5%
10 years, per year —+5.2%+7.6% +13.3%

Risk

MeasureELANZTSICCCSPY
Volatility, 1Y 43.4%39.7%50.5% 13.6%
Downside volatility, 1Y 43.7%46.6%47.9% 13.9%
Beta vs S&P 500, 1Y 1.320.610.45 1.00
Return / volatility, 1Y 0.50-0.781.54 0.90
Max drawdown, 5Y -75.0%-72.0%-67.0% -25.4%
From 52-week high -0.2%-36.1%-8.3% -3.2%
52-week high $26.84$131.10$11.72 $779.14
52-week low $19.80$69.12$4.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleELANZTSICCC
P/E now vs peer median -91.1xmedian 17.0x 13.8xmedian 17.0x 52.0xmedian 17.0x
P/S now vs peer median 2.6xmedian 8.4x 3.6xmedian 8.4x 2.9xmedian 8.4x
EV/EBITDA now vs peer median 11.8xmedian 14.6x 10.4xmedian 14.6x 14.0xmedian 14.6x
P/FCF now vs peer median 32.8xmedian 19.0x 15.3xmedian 19.0x 18.1xmedian 19.0x
P/B now vs peer median 2.0xmedian 2.0x 10.3xmedian 2.0x 3.0xmedian 2.0x
PEG now vs peer median -1.82median 0.43 1.91median 0.43 1.68median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsELANZTSICCC
Revenue $5.15B $9.49B $33.21M
Gross profit $2.89B $6.80B $13.56M
Operating income $720.00M $3.54B $4.80M
Net income -$147.00M $2.51B $1.88M
Free cash flow $408.00M $2.24B $5.40M
R&D $381.00M $722.00M $1.37M
EPS (diluted) $-0.29 $6.09 $0.20
Cash & equivalents $465.00M $1.33B $7.91M
Total debt $3.71B $9.05B $7.90M
Shares (diluted) 506.50M 411.60M 9.30M
Enterprise value $11.29B $27.05B $75.03M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricELANZTSICCC
P/E -91.1x 13.8x 52.0x
P/FCF 32.8x 15.3x 18.1x
P/Operating cash flow 21.8x 12.5x 12.5x
P/S 2.6x 3.6x 2.9x
P/B 2.0x 10.3x 3.0x
P/Tangible book 3.7x 13.9x 3.0x
EV/EBITDA 11.8x 10.4x 14.0x
EV/EBIT 23.1x 11.8x 20.3x
EV/Revenue 3.2x 4.4x 2.9x
EV/FCF 40.8x 18.6x 18.1x
EV/Operating cash flow 27.1x 15.3x 12.5x
PEG (3Y EPS CAGR) -1.82 1.91 1.68

Growth

14 metrics
MetricELANZTSICCC
Revenue growth (1Y) 12.1% 0.9% 19.6%
Revenue CAGR (3Y) 5.6% 4.3% 26.8%
Gross profit growth (1Y) 14.6% 1.0% 19.3%
Gross profit CAGR (3Y) 4.9% 4.9% 55.5%
Operating income growth (1Y) 20.6% -1.7% 106.3%
Operating income CAGR (3Y) 41.2% 4.0% 40.2%
Net income growth (1Y) -508.3% -4.7% -19.1%
Net income CAGR (3Y) 49.5% 3.2% 32.0%
EPS growth (1Y) -500.5% 2.6% -21.3%
EPS CAGR (3Y) 50.0% 7.2% 31.0%
Operating cash flow growth (1Y) -2.4% -7.9% 293.6%
Operating cash flow CAGR (3Y) 69.1% 7.5% 51.7%
Free cash flow growth (1Y) 10.9% -2.1% 655.1%
Free cash flow CAGR (3Y) 117.8% 14.4% 37.9%

Profitability

14 metrics
MetricELANZTSICCC
Gross margin 56.2% 71.6% 40.8%
EBITDA margin 27.5% 42.4% 21.1%
Operating margin 14.0% 37.3% 14.5%
Pretax margin -1.8% 33.1% 5.8%
Net margin -2.9% 26.4% 5.7%
FCF margin 7.9% 23.5% 16.3%
Operating cash flow margin 11.9% 28.7% 23.6%
Return on equity -2.2% 77.7% 5.9%
Return on assets -1.1% 16.6% 4.0%
Return on invested capital 6.9% 23.0% 11.7%
Return on capital employed 6.2% 28.6% 11.3%
Asset turnover 0.4x 0.6x 0.7x
Cash conversion (OCF / net income) -4.2x 1.1x 4.2x
Stock comp / revenue 1.5% 1.1% 2.6%

Financial Health

11 metrics
MetricELANZTSICCC
Debt / assets 27.8% 60.0% 16.5%
Debt / equity 0.6x 2.7x 0.2x
Net debt / EBITDA 2.3x 1.9x 0.0x
Debt / FCF 9.1x 4.0x 1.5x
Liabilities / assets 50.3% 78.1% 31.7%
Equity / assets 49.7% 21.9% 68.3%
Interest coverage 2.8x 14.6x 12.2x
Current ratio 2.1x 2.3x 4.6x
Quick ratio 0.9x 1.2x 2.4x
Cash ratio 0.3x 0.6x 1.7x
Altman Z-score 1.72 4.85 5.00

Shareholder Returns

7 metrics
MetricELANZTSICCC
Dividend yield – 2.5% –
Net buyback yield -0.3% 11.0% -0.2%
Shareholder yield -0.3% 13.5% -0.2%
Payout ratio (earnings) – 35.3% –
Payout ratio (FCF) – 39.6% –
Dividend growth (1Y) – 2.7% –
Dividend CAGR (3Y) – 9.7% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusELANZTSICCC
Forward P/E 23.7xFY2026 14.1xFY2026 –
EPS, next fiscal year $1.13FY2026 $5.96FY2026 –
EPS growth, next FY +20.2%FY2026 -7.0%FY2026 –
EPS growth, the year after +22.1% +10.1% –
Revenue, next fiscal year $4.82BFY2026 $9.59BFY2026 –
Revenue growth, next FY +2.4%FY2026 +1.3%FY2026 –
Revenue growth, the year after +19.4% -9.0% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersELANZTSICCC
Held by institutions 100.0% 94.7% 15.0%
Institutions holding 526 1,419 32
Change in shares held, QoQ +4.4% -2.6% -2.6%
Institutions buying 246 674 15
Institutions selling 211 584 7
Buyers to sellers 1.17 1.15 2.14

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ELANZTSICCC
ELAN 1.00 0.47 -0.03
ZTS 0.47 1.00 0.11
ICCC -0.03 0.11 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ELAN, ZTS and ICCC?

Zoetis (ZTS) is the largest by market capitalisation: Elanco Animal Health (ELAN) $13.25B, Zoetis (ZTS) $34.65B, Immucell (ICCC) $102.43M.

Which stock is cheaper, ELAN, ZTS and ICCC?

Zoetis (ZTS) trades on the lowest price-to-earnings ratio (Elanco Animal Health (ELAN) -90.2x, Zoetis (ZTS) 13.8x, Immucell (ICCC) 54.5x). On next year's consensus earnings, Zoetis (ZTS) is cheapest (Elanco Animal Health (ELAN) 23.7x, Zoetis (ZTS) 14.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Immucell (ICCC) grew revenue fastest over the trailing twelve months: Elanco Animal Health (ELAN) +12.1%, Zoetis (ZTS) +0.9%, Immucell (ICCC) +19.6%.

Which company is more profitable?

Zoetis (ZTS) has the highest net margin (Elanco Animal Health (ELAN) -2.9%, Zoetis (ZTS) 26.4%, Immucell (ICCC) 5.7%). On return on invested capital, Zoetis (ZTS) leads (Elanco Animal Health (ELAN) 6.9%, Zoetis (ZTS) 23.0%, Immucell (ICCC) 11.7%).

Which stock has performed better?

Over the past year Immucell (ICCC) returned the most: Elanco Animal Health (ELAN) +21.8%, Zoetis (ZTS) -30.8%, Immucell (ICCC) +77.7%. Over five years, Immucell (ICCC) compounded fastest (Elanco Animal Health (ELAN) -4.1%/yr, Zoetis (ZTS) -17.3%/yr, Immucell (ICCC) +3.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Elanco Animal Health (ELAN) 0.00%, Zoetis (ZTS) 0.03%, Immucell (ICCC) 0.00%. Elanco Animal Health (ELAN) and Immucell (ICCC) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Zoetis (ZTS) has been the steadiest (Elanco Animal Health (ELAN) 43.4%, Zoetis (ZTS) 39.7%, Immucell (ICCC) 50.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ELAN, ZTS and ICCC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Zoetis (ZTS) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.